Sandoz Agrees to $450 Million U.S. Settlement Over Generic-Drug Claims, Keeps Guidance Unchanged
Sandoz Group AG has reached a $450 million settlement to resolve U.S. litigation brought by 43 states and territories alleging anti-competitive conduct in the generic medicines market. The company said the payment includes $400 million to be paid by its U.S. subsidiary in installments over seven years beginning in 2027, plus roughly $50 million to …